All In Biotech

Drug Trial Radar · NCT06516419

Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma Therapy

Last checked: Nov 19, 2026Latest source record: Jul 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

90

Planned (sponsor's estimate)

Start

Feb 13, 2024

Primary completion

Mar 30, 2025

Study completion Mar 30, 2025

Sponsor

Lead sponsor
Dr.dr.Irma Bernadette, SpKK (K)Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
Female only, from 30 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This research is a clinical study with a single-blind randomized clinical trial design (randomized controlled trial) in RSCM-FKUI This study aims to Assess the effectiveness and safety of intradermal concentrated secretome injection therapy, triple combination cream, and intradermal tranexamic acid injection in melasma patients, determine the quality of life profile of melasma patients after triple combination cream therapy in melasma therapy, and determine SOD levels in melasma patients. This research will be attended by 90 research subjects

Conditions

  • Melasma

Interventions

  • Concentrated secretome Injection 2mLDrug

    The secretome used in this research comes from mesenchymal stem cells from adipose tissue produced by IPT RSCM Stem Cell Medical Technology. The secretome produced by mesenchymal stem cells is collected, centrifuged to separate it from debris, and followed by filtration with a 0.22 μm pore filter to ensure sterility. Next, the concentration process is carried out using tangential flow filtration with the Spin-X UF 500® concentrator, packaged, and stored at -80 degrees Celsius. The product used is a sterile product, which is tested for sterility and total protein content. When it is to be used, the secretome is removed from the freezer, warmed (thawing), and injected into the patient according to a predetermined method.

  • Tranexamic acid injectionDrug

    1. Tranexamic acid 25 mg/ml is prepared by taking tranexamic acid in a vial 250 mg/5 ml as much as 0.5 ml (25 mg) using a 1 ml syringe and diluted with 0.5 ml 0.9% NaCl solution just before being injected into the SP. 2. Tranexamic acid 10 mg/ml is prepared by taking 0.2 ml (10 mg) of AT in a 250 mg/5 ml vial using a 1 ml syringe and diluting it with 0.8 ml of 0.9% NaCl solution for a moment. before injection into the Subject 2\. Tranexamic acid 10 mg/ml is prepared by taking 0.2 ml (10 mg) of AT in a 250 mg/5 ml vial using a 1 ml syringe and diluting it with 0.9% normal saline (NS) 0.8 ml just before injection into the Subject

  • Triple Combination CreamDrug

    1. Apply sunscreen SPF ≥30 in the morning on 2 knuckles 2. Apply triple combination cream (Refaquin) containing hydroquinone 40 mg, tretinoin 0.5 mg, and fluocinolone acetonide 0.1 mg at night all over the face except the area around the eyes, 1 fingertip unit (FTU) or 1 knuckle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of Melasma Severity based on modified Melasma Severity Index (mMASI) score.Time frame: re-evaluation on day 14, 28, 42, 56 and day 84 of therapy
  2. Change of Melasma Severity based on Patient's Tolerability Assesment (PtGA).Time frame: re-evaluation on day 14, 28, 42, 56 and day 84 of therapy
  3. Change of Melasma Severity based on DermoscopyTime frame: re-evaluation on day 84 of therapy
  4. Change of Melasma Severity based on Wood's LampTime frame: re-evaluation on day 84 of therapy
  5. Compare Quality Of Life based on MelasQoL ScoreTime frame: re-evaluation on day 84 of therapy
  6. Change of Melanin Index Based on MexameterTime frame: re-evaluation on day 14, 28, 42, 56 and day 84 of therapy
  7. Change of Erytema Index Based on MexameterTime frame: re-evaluation on day 14, 28, 42, 56 and day 84 of therapy

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Supporting Unit- Faculty of Medicine, University of Indonesia

    Jakarta Pusat, DKI Jakarta, Indonesia · Recruiting

  • Dr. Cipto Mangunkusumo Hospital

    Jakarta Pusat, DKI Jakarta, Indonesia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.